LRMR (Larimar Therapeutics) Other Operating Expense: $0.00 Mil (TTM As of Mar. 2026)


LRMR Larimar Therapeutics Inc LRMR
34 GF Score
Price $4.29
! 2 Warning Signs
View Full Analysis

What is Larimar Therapeutics Other Operating Expense?

Larimar Therapeutics LRMR +3.63% 34 Other Operating Expense is $0.00 Mil as of Mar. 2026. GuruFocus rates LRMR with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Larimar Therapeutics's Other Operating Expense for the three months ended in Mar. 2026 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Larimar Therapeutics's quarterly Other Operating Expense declined from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.00 Mil) and declined from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Larimar Therapeutics's annual Other Operating Expense declined from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($-0.00 Mil) but then increased from Dec. 2024 ($-0.00 Mil) to Dec. 2025 ($0.00 Mil).

Larimar Therapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Larimar Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Larimar Therapeutics Other Operating Expense Chart

Larimar Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial 0.00 0.00 0.00 -0.00 0.00

Larimar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 0.00
LRMR
34GF Score
Larimar Therapeutics Inc LRMR
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Larimar Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $0.00 Mil mean?
Larimar Therapeutics (LRMR) has a Other Operating Expense of $0.00 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Larimar Therapeutics and its competitors.
Is Larimar Therapeutics' Other Operating Expense too high?
Larimar Therapeutics' current Other Operating Expense is $0.00 Mil. Overall, Larimar Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Larimar Therapeutics' Other Operating Expense compare to XFOR and CMPX?
Larimar Therapeutics' Other Operating Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Larimar Therapeutics and its competitors. Larimar Therapeutics's current Other Operating Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Larimar Therapeutics stock overvalued right now?
Larimar Therapeutics (LRMR) has a current Other Operating Expense of $0.00 Mil. The current Other Operating Expense is $0.00 Mil. Larimar Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Larimar Therapeutics (LRMR), the current Other Operating Expense is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Larimar Therapeutics Business Description

Other Exchanges ZA71:Germany
Address Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
34GF Score

Get the complete analysis for LRMR

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.29
Price